

Supplemental Material for “Emulated Clinical Trials from Longitudinal Real-World Data Efficiently Identify Candidates for Neurological Disease Modification: Examples from Parkinson's Disease”

Table S1. ICD codes for PD cohort definition

Type	System	Code	Name
Inclusion	icd9	3320	Paralysis agitans
	icd10	G20	Parkinson's disease
Exclusion	icd9	3316	Corticobasal degeneration
	icd9	3321	Secondary parkinsonism
	icd9	3330	Other degenerative diseases of the basal ganglia
	icd10	G21	Secondary parkinsonism
	icd10	G231	Progressive supranuclear ophthalmoplegia [Steele-Richardson-Olszewski]
	icd10	G3185	Corticobasal degeneration

Table S2. PD-indicated drugs and their corresponding ATC class names. The list below has been compiled by a domain expert based on the following sources: National Drug File – Reference Terminology (NDF-RT), Anatomical Therapeutic Chemical Classification System (ATC), and DrugBank (45).

Drug	ATC class code(s)	ATC class name(s)
Amantadine	N04BB	Adamantane derivatives
Apomorphine	G04BE; N04BC	Drugs used in erectile dysfunction; dopamine agonists
Atropine	A03BA; S01FA	Belladonna alkaloids, tertiary amines; anticholinergics
Benztropine	N04AC	Ethers of tropine or tropine derivatives
Biperiden	N04AA	Tertiary amines
Bornaprine	N04AA	Tertiary amines
Bromocriptine	G02CB; N04BC	Prolactine inhibitors; dopamine agonists
Budipine	N04BX	Other dopaminergic agents

Cabergoline	G02CB; N04BC	Prolactine inhibitors; dopamine agonists
Carbidopa	N/A	N/A
Dexetimide	N04AA	Tertiary amines
Dihydroergocryptine	N04BC	Dopamine agonists
Entacapone	N04BX	Other dopaminergic agents
Hyoscyamine	A03BA	Belladonna alkaloids, tertiary amines
Levodopa	N04BA	Dopa and dopa derivatives
Methixene	N04AA	Tertiary amines
Orphenadrine	N04AB; M03BC	Ethers chemically close to antihistamines; ethers, chemically close to antihistamines
Pergolide	N04BC	Dopamine agonists
Piribedil	N04BC	Dopamine agonists
Pramipexole	N04BC	Dopamine agonists
Procyclidine	N04AA	Tertiary amines
Profenamine	N04AA	Tertiary amines
Rasagiline	N04BD	Monoamine oxidase B inhibitors
Ropinirole	N04BC	Dopamine agonists
Rotigotine	N04BC	Dopamine agonists
Selegiline	N04BD	Monoamine oxidase B inhibitors
Tolcapone	N04BX	Other dopaminergic agents
Trihexyphenidyl	N04AA	Tertiary amines
Tropatepine	N04AA	Tertiary amines

Table S3. PD outcome definitions.

Outcome	System	Code	Name
Fall	ICD9	E88	Accidental falls
	ICD10	W0, W1	Falls

Outcome	System	Code	Name
Psychosis	ICD9	292	Drug-induced mental disorders
		297	Delusional disorders
		298	Other nonorganic psychoses
	ICD10	F2	Schizophrenia, schizotypal and delusional disorders
Dementia	ICD9	294	Persistent mental disorders due to conditions classified elsewhere
		331	Other cerebral degenerations
	ICD10	F01	Vascular dementia
		F02	Dementia in other diseases classified elsewhere
		F03	Unspecified dementia
		G30	Alzheimer disease

Table S4. Rasagiline cohort characteristics. Shown are the mean, standard deviation (in parentheses), and the first, second (median), and third quartile (in brackets).

	MarketScan	Explorys
Patient count	3,094	1,988
Patient timeline [years]		
Total	4.1 (1.0) [3.0; 4.6; 5.0]	(5.1) [7.0; 10.6; 14.8]
Before first PD diagnosis	2.5 (1.0) [1.6; 2.4; 3.2]	(4.8) [3.3; 6.3; 10.6]
After first PD diagnosis	1.6 (1.0) [0.8; 1.5; 2.4]	3.9 (2.5) [2.0; 3.5; 5.4]
No. of unique prescribed drugs	15.6 (9.3) [9.0; 14.0; 21.0]	20.7 (18.2) [7.0; 15.0; 29.0]
Insurance		
Medicare, Medicaid, other public	60%	80%
Commercial, private only	40%	18%
Other or unknown	0%	2%
Baseline characteristics (during ≤1 year before diagnosis)		
Age at first diagnosis	68.5 (8.5) [61.8; 66.2; 74.7]	70.7 (7.7) [64.8; 70.4; 76.4]
Women	38%	37%

PD progression		
Falls	3%	4%
Psychosis	1%	1%
<u>Comorbidities (during ≤1 year before diagnosis)</u>		
Charlson's Comorbidity Index	1.1 (1.5) [0.0; 0.0; 2.0]	0.6 (1.2) [0.0; 0.0; 1.0]
Diabetes mellitus		
with no complications	17.70%	10.82%
with chronic complications	5.04%	2.82%
Cerebrovascular Disease	15.30%	6.39%
COPD	10.50%	4.83%
Malignancy	10.00%	7.09%
Peripheral Vascular Disease	8.21%	4.28%
Congestive Heart Failure	4.88%	3.22%
Kidney Disease	4.36%	3.87%
Rheumatic Disease	3.01%	1.11%
Myocardial Infarction	2.07%	1.66%
Mild Liver Disease	1.65%	1.26%
Hemiplegia Paraplegia	1.42%	0.50%
Dementia	0.65%	0.25%
Peptic Ulcer Disease	0.58%	0.30%
Severe Liver Disease	0.10%	0.10%
Follow-up characteristics (during ≤2 years following diagnosis)		
PD Progression		
Dementia	15% [†] (11%)	12% [†] (11%)
Charlson's Comorbidity Index	1.4 (1.9) [0.0; 1.0; 2.0]	1.1 (1.8) [0.0; 0.0; 2.0]

† 15% and 12% are Kaplan-Mayer estimators in MarketScan and Explorys resp., which adjust for censoring.

Table S5. Zolpidem cohort characteristics. Shown are the mean, standard deviation (in parentheses), and the first, second (median), and third quartile (in brackets).

	MarketScan	Explorys
--	------------	----------

Patient count	847	1,828
Patient timeline [years]		
Total	4.0 (1.1) [3.0; 4.1; 5.0]	11.4 (5.1) [7.2; 11.1; 15.2]
Before first PD diagnosis	2.2 (1.0) [1.4; 2.0; 2.8]	7.5 (4.7) [3.6; 6.7; 10.7]
After first PD diagnosis	1.8 (1.1) [0.9; 1.6; 2.6]	3.9 (2.6) [1.8; 3.4; 5.4]
No. of unique prescribed drugs	25.1 (12.7) [16.0; 23.0; 32.0]	40.3 (25.8) [20.0; 35.0; 55.0]
Insurance		
Medicare, Medicaid, other public	77%	83%
Commercial, private only	23%	9%
Other or unknown	0%	8%
Baseline characteristics (during ≤1 year before diagnosis)		
Age at first diagnosis	71.4 (10.1) [62.6; 70.0; 79.5]	73.9 (7.8) [67.8; 74.8; 80.2]
Women	43%	45%
PD progression		
Falls	8%	11%
Psychosis	5%	4%
Comorbidities (during ≤1 year before diagnosis)		
Charlson's Comorbidity Index	2.1 (2.3) [0.0; 1.0; 3.0]	1.7 (2.1) [0.0; 1.0; 3.0]
Diabetes mellitus		
with no complications	28.60%	25.44%
with chronic complications	12.80%	7.28%
COPD	25.00%	21.55%
Cerebrovascular Disease	21.50%	13.07%
Congestive Heart Failure	17.70%	14.39%
Peripheral Vascular Disease	14.40%	10.72%
Kidney Disease	14.00%	14.00%
Malignancy	12.50%	9.85%
Myocardial Infarction	5.90%	7.33%
Mild Liver Disease	4.13%	2.30%
Rheumatic Disease	2.95%	3.23%
Dementia	2.48%	0.60%

Hemiplegia Paraplegia	1.77%	1.09%
Peptic Ulcer Disease	1.77%	2.08%
Severe Liver Disease	0.59%	0.22%
Follow-up characteristics (during ≤2 years following diagnosis)		
PD Progression		
Dementia	26% [†] (20%)	23% [†] (21%)
Charlson's Comorbidity Index	2.8 (2.9) [0.0; 2.0; 4.0]	3.0 (3.0) [1.0; 2.0; 5.0]

† 26% and 23% are Kaplan-Mayer estimators in MarketScan and Explorys resp., which adjust for censoring.

Table S6. N04 cohort characteristics. Shown are the mean, standard deviation (in parentheses), and the first, second (median), and third quartile (in brackets).

	MarketScan	Explorys
Patient count	10,289	12,408
Patient timeline [years]		
Total	4.1 (1.0) [3.1; 4.8; 5.0]	10.9 (5.1) [6.8; 10.5; 14.6]
Before first PD diagnosis	2.5 (1.1) [1.6; 2.3; 3.3]	(4.7) [3.6; 6.5; 10.6]
After first PD diagnosis	1.6 (1.0) [0.8; 1.4; 2.4]	3.5 (2.6) [1.5; 2.8; 4.8]
No. of unique prescribed drugs	17.4 (10.4) [10.0; 16.0; 23.0]	18.3 (17.8) [5.0; 13.0; 25.0]
Insurance		
Medicare, Medicaid, other public	79%	82%
Commercial, private only	21%	12%
Other or unknown	0%	6%
Baseline characteristics (during ≤1 year before diagnosis)		
Age at first diagnosis	73.3 (9.8) [64.6; 73.6; 81.1]	73.7 (7.9) [67.9; 74.5; 79.9]
Women	42%	44%
PD progression		
Falls	5%	4%
Psychosis	3%	1%
Comorbidities (during ≤1 year before diagnosis)		

Charlson's Comorbidity Index	1.7 (2.0) [0.0; 1.0; 3.0]	0.8 (1.3) [0.0; 0.0; 1.0]
Diabetes mellitus		
with no complications	25.80%	14.74%
with chronic complications	9.71%	3.48%
Cerebrovascular Disease	22.10%	8.13%
COPD	17.50%	7.87%
Peripheral Vascular Disease	14.20%	4.80%
Malignancy	11.60%	6.58%
Congestive Heart Failure	10.90%	4.69%
Kidney Disease	9.56%	4.89%
Myocardial Infarction	3.82%	2.09%
Rheumatic Disease	3.43%	1.91%
Mild Liver Disease	2.66%	1.20%
Dementia	2.35%	0.30%
Hemiplegia Paraplegia	2.31%	0.60%
Peptic Ulcer Disease	1.28%	0.58%
Severe Liver Disease	0.34%	0.13%
Follow-up characteristics (during ≤2 years following diagnosis)		
PD progression		
Dementia	28% [†] (21%)	19% [†] (17%)
Charlson's Comorbidity Index	2.2 (2.5) [0.0; 1.0; 3.0]	1.6 (2.1) [0.0; 1.0; 2.0]

† 28% and 19% are Kaplan-Mayer estimators in MarketScan and Explorys resp., which adjust for censoring.

Table S7. N05 cohort characteristics. Shown are the mean, standard deviation (in parentheses), and the first, second (median), and third quartile (in brackets).

	MarketScan	Explorys
Patient count	3,116	9,067
Patient timeline [years]		
Total	4.0 (1.1) [3.0; 4.2; 5.0]	(5.0) [6.5; 9.6; 14.1]
Before first PD diagnosis	2.3 (1.0) [1.5; 2.1; 3.0]	(4.6) [3.4; 6.1; 10.1]

After first PD diagnosis	1.7 (1.1) [0.8; 1.5; 2.6]	3.3 (2.4) [1.5; 2.8; 4.5]
No. of unique prescribed drugs	19.4 (10.0) [12.0; 18.0; 25.0]	24.4 (17.8) [11.0; 20.0; 33.0]
Insurance		
Medicare, Medicaid, other public	83%	84%
Commercial, private only	17%	9%
Other or unknown	0%	7%
Baseline characteristics (during ≤1 year before diagnosis)		
Age at first diagnosis	74.0 (9.9) [65.1; 74.4; 82.1]	(7.9) [68.9; 75.4; 80.8]
Women	48%	45%
PD progression		
Falls	6%	10%
Psychosis	7%	4%
Comorbidities (during ≤1 year before diagnosis)		
Charlson's Comorbidity Index	1.8 (2.1) [0.0; 1.0; 3.0]	1.1 (1.7) [0.0; 0.0; 2.0]
Diabetes mellitus		
with no complications	24.80%	19.44%
with chronic complications	9.11%	4.88%
Cerebrovascular Disease	20.10%	10.09%
COPD	19.80%	13.60%
Peripheral Vascular Disease	15.60%	7.28%
Congestive Heart Failure	14.20%	10.18%
Malignancy	10.30%	7.59%
Kidney Disease	9.24%	8.16%
Myocardial Infarction	5.33%	4.58%
Dementia	4.72%	0.73%
Rheumatic Disease	3.53%	2.44%
Mild Liver Disease	2.76%	1.57%
Hemiplegia Paraplegia	2.18%	1.07%
Peptic Ulcer Disease	1.38%	0.83%
Severe Liver Disease	0.42%	0.19%

Follow-up characteristics (during ≤2 years following diagnosis)		
PD progression		
Dementia	38% [†] (30%)	29% [†] (27%)
Charlson's Comorbidity Index	2.4 (2.7) [0.0; 2.0; 4.0]	2.3 (2.6) [0.0; 2.0; 4.0]

† 38% and 29% are Kaplan-Mayer estimators in MarketScan and Explorys resp., which adjust for censoring.

Table S8. Estimated effects on dementia onset for emulated RCTs involving rasagiline and its encompassing ATC classes. For composition of treatment and control cohorts, Table S10. Beneficial effect is highlighted in green and non-beneficial effect is highlighted in Red.

		Control cohort							
		N04BD		N04B		N04		N	
		Estimated effects							
		Weight balancing	Outcome model	Weight balancing	Outcome model	Weight balancing	Outcome model	Weight balancing	Outcome model
		MarketScan							
Treatment cohort	Rasagiline	-0.009	-0.06	-0.09	-0.07	-0.09	-0.07	-0.09	-0.07
	N04BD			-0.08	-0.06	-0.08	-0.06	-0.08	-0.06
	N04B					0.13	-0.08	Failed to balance cohorts	
	N04							Failed to balance cohorts	
		Explorys							
Treatment cohort	Rasagiline	-0.06	-0.08	-0.09	-0.07	-0.08	-0.07	-0.09	-0.09
	N04BD			-0.11	-0.11	-0.11	-0.1	-0.08	-0.08
	N04B					Failed to balance cohorts		-0.00013	-0.11
	N04							-0.01	-0.1

Table S9. Estimated effects on dementia onset for emulated RCTs involving zolpidem and its encompassing ATC classes. For composition of treatment and control cohorts, see Table S10. Beneficial effect is highlighted in green and non-beneficial effect is highlighted in Red.

		Control cohort							
		N05CF		N05C		N05		N	
		Estimated effects							
		Weight balancing	Outcome model	Weight balancing	Outcome model	Weight balancing	Outcome model	Weight balancing	Outcome model
		MarketScan							
Treatment cohort	Zolpidem	-0.03	-0.1	-0.13	-0.13	-0.12	-0.1	-0.09	-0.04
	N05CF			-0.13	-0.12	-0.13	-0.12	-0.08	-0.05
	N05C					-0.06	-0.07	-0.05	-0.006
	N05							0.03	0.02
		Explorys							
Treatment cohort	Zolpidem	Control cohort too small	0.01	0.006	-0.08	-0.08	-0.02	-0.01	
	N05CF		0.03	0.01	-0.06	-0.07	-0.02	-0.01	
	N05C				-0.12	-0.11	-0.06	-0.03	
	N05						0.07	0.02	